TransMedics Group (TMDX) 46th Annual William Blair Growth Stock Conference summary

Key innovations and market impact

• Developed a portable, physiologic organ care system (OCS) that preserves and enhances organ viability, enabling real-time assessment and treatment during transport.

• Expanded from heart, lung, and liver to a next-generation kidney platform, targeting the largest transplant market segment.

• Created a national service network (NOP) with 19 hubs, 22 dedicated aircraft, and 140 pilots, vertically integrating logistics to ensure equitable access and maximize organ utilization.

• Proprietary digital ecosystem enables transparency, scalability, and efficient coordination among clinical stakeholders.

• Achieved the highest reported organ utilization rates globally, with 26% of U.S. transplant volume managed through their network last year.

Growth strategy and future outlook

• Set targets to reach 10,000 U.S. transplants by 2028, 20,000 by 2030, and 30,000 global transplants by 2032, driven by kidney platform launch and international expansion.

• 2026–2027 will be investment-heavy, focusing on Gen 2 technology for heart and lung, and launching the kidney platform in 2027.

• Plans to introduce remotely monitored, cloud-based OCS Gen 3 for scalable, efficient operations.

• International expansion, especially in Europe, is a key long-term growth driver, with European partners seeking to replicate the U.S. NOP model.

• Focused on growing revenue from $605 million to $2.5–$3 billion over the next four to five years, prioritizing growth over short-term EPS.

Financial performance and competitive positioning

• Delivered double-digit revenue growth and achieved profitability last year, with guidance for 20–25% growth in 2026.

• Demonstrated that national transplant volume grew 25% over three years due to their platform, while it would have declined without it.

• Launched new products (ENHANCE Heart, DENOVO Lung, CHOPS) to expand into untapped market segments and further differentiate from competitors.

• Committed to clinical excellence, conducting large-scale trials to set industry standards and maintain regulatory leadership.

• Leadership and team dedication highlighted as critical to scaling operations and maintaining best-in-class outcomes.